drugset / Trial / NCT00122850

A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder

NCT00122850

Phase 3 Completed 480 enrolled Eli Lilly and Company Boehringer Ingelheim · collab
RandomizedSingle-groupDouble-blindTreatment

Summary

This study will examine duloxetine compared with placebo and an active comparator in the treatment of generalized anxiety disorder.

Timeline

Start
2004-10
Primary completion
Completion
2005-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg
Subject Duloxetine Small molecule 120 mg
Subject Venlafaxine Small molecule 75 mg
Subject Venlafaxine Small molecule 225 mg

Indications